Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access               Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain LOXO message board posts where the ticker symbol LOXO has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest LOXO SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001140361-18-024225 Size: 24 KB
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001140361-18-024223 Size: 16 KB
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001140361-18-024219 Size: 35 KB
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001104659-18-031328 (34 Act)  Size: 4 MB
2018-05-08 001-36562
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001104659-18-031064 (34 Act)  Size: 183 KB
2018-05-08 001-36562
DEFA14A  Documents Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Acc-no: 0001104659-18-028594 (34 Act)  Size: 272 KB
2018-04-30 001-36562
DEF 14A  Documents Other definitive proxy statements
Acc-no: 0001104659-18-028592 (34 Act)  Size: 1 MB
2018-04-30 001-36562
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001140361-18-019774 Size: 14 KB
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001140361-18-019771 Size: 25 KB
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001140361-18-019768 Size: 29 KB
More LOXO SEC Filings

Related news from
Sat, 19 May 2018
13:32:00 +0000
Does a Blue Ribbon Make This Biotech Stock a Buy Now?
This biotech could wow the crowd at ASCO again. Here's what you need to know.
Fri, 18 May 2018
20:51:00 +0000
Winners and Losers From the Biggest Cancer Meeting of the Year (So Far)
The meeting hasn't even started, and stocks are already moving.
Fri, 18 May 2018
14:16:00 +0000
This Tiny Cancer Drug Upstart Just Got Even More Interesting
A clinical-stage cancer drug company could be on the cusp of a second big win.
Fri, 18 May 2018
12:10:00 +0000
Today’s Research Reports on Stocks to Watch: Loxo Oncology and Jounce Therapeutics
NEW YORK, NY / ACCESSWIRE / May 18, 2018 / Both Loxo Oncology and Jounce Therapeutics shares went in different directions after traders absorbed abstract reveals from each company. Shares of Loxo soared ...
Thu, 17 May 2018
17:52:00 +0000
Here's Why Loxo Oncology Rose as Much as 23.3% Today
Good news keeps rolling in for the clinical stage biopharma.
Thu, 17 May 2018
14:39:52 +0000
Loxo Oncology shares surge 21% on preview of cancer drug trial data
Loxo Oncology Inc. shares surged 20.8% in heavy Thursday morning trade after the company released a preview of early data for its cancer drug LOXO-292. The data, which will be presented at the American Society of Clinical Oncology's annual meeting in early June, looks at interim data from an ongoing phase 1 clinical trial for LOXO-292. The results were impressive, with apparently "unremarkable" safety data, said Stifel analyst Stephen D. Willey, who now expects peak U.S. sales for the drug of more than $800 million.
Thu, 17 May 2018
13:31:29 +0000
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Walmart Inc (NYSE: WMT ) was trading higher by nearly ...
Thu, 17 May 2018
13:19:11 +0000
UPDATE 1-Loxo Oncology's targeted RET drug shows promise in early trial
An experimental Loxo Oncology Inc drug that targets cancers with mistakes in the RET gene led to tumor shrinkage in nearly 70 percent of patients regardless of where their cancer originated, according to preliminary data from a small study released on Wednesday. The drug, LOXO-292, was well tolerated by patients with advanced cancer, many of whom were resistant to or no longer being helped by available treatments, researchers reported. Loxo shares rose more than 9 percent after the data was released, while shares of Blueprint Medicines, which is developing a rival drug, fell more than 12 percent.
Thu, 17 May 2018
11:15:32 +0000
Dow Jones Futures Today: These 2 Tech Stocks Near Buys Move On Earnings; This Biotech Soars
Dow Jones futures fell Thursday. Cisco Systems and Take-Two Interactive, both near buy points, fell on earnings. Loxo Oncology spiked on cancer drug trial data.
Wed, 16 May 2018
21:38:00 +0000
After-hours buzz: CSCO, JACK & more
See which stocks are posting big moves after the bell.
Wed, 16 May 2018
21:00:00 +0000
Loxo Oncology Announces Details of LOXO-292 Clinical Data Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
–LOXO-292 Phase 1 Clinical Trial Abstract Selected for“ Best of ASCO”–. –Company to Host Conference Call and Webcast on Saturday, June 2 nd at 4:00 p.m. CT–. STAMFORD, Conn., May 16, 2018-- Loxo Oncology, ...
Tue, 15 May 2018
19:52:02 +0000
Edited Transcript of LOXO earnings conference call or presentation 8-May-18 12:00pm GMT
Q1 2018 Loxo Oncology Inc Earnings Call
Tue, 08 May 2018
10:45:00 +0000
Loxo Oncology Reports First Quarter 2018 Financial Results
-LOXO-292 Phase 1 Oral Presentation Upcoming at 2018 ASCO Annual Meeting-. -LOXO-292 Preclinical and Clinical Proof-of-Concept Data Published in Annals of Oncology-. -Rolling Submission for Larotrectinib ...
Mon, 07 May 2018
20:30:00 +0000
Loxo Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Loxo Oncology, Inc. (LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that between April 23, 2018 and May 7, 2018, the Compensation Committee of Loxo Oncology’s Board of Directors granted non-qualified stock options to purchase an aggregate of 98,525 shares of its common stock to thirteen new employees.
Tue, 01 May 2018
10:45:00 +0000
Loxo Oncology to Announce First Quarter 2018 Financial Results
STAMFORD, Conn., May 01, 2018-- Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, will announce financial ...
Tue, 24 Apr 2018
12:27:00 +0000
How Blueprint Medicines Got The Blues
Last Sunday, lots of people were gushing about Blueprint Medicines' experimental cancer drug. The answer: biotech fund managers are paying attention to a scientist who poked holes in Blueprint's data on-stage at the annual meeting of the American Association for Cancer Research, the same venue where Blueprint presented its data. Loxo's shares are up 8% since Blueprint's data were presented.
Tue, 17 Apr 2018
15:41:03 +0000
Loxo Oncology (LOXO) Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Loxo Oncology, Inc. (LOXO).
Tue, 17 Apr 2018
12:10:00 +0000
Today’s Research Reports on Stocks to Watch: Clovis Oncology and Loxo Oncology
NEW YORK, NY / ACCESSWIRE / April 17, 2018 / Clovis Oncology saw its shares close down over 10% on Monday after announcing that it has commenced two separate underwritten public offerings. Shares of Loxo ...
Mon, 16 Apr 2018
13:52:20 +0000
Morgan Stanley Upgrades Loxo On The Potential Of A Targeted Cancer Therapy
Loxo Oncology Inc (NASDAQ: LOXO ) holds an opportunity to differentiate itself among RET inhibitors while developing medicines for patients with genetically defined cancers, according to Morgan Stanley.  ...
Mon, 16 Apr 2018
12:07:07 +0000
See what the IHS Markit Score report has to say about Loxo Oncology Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "This last year I have subscribed to two investment services, ValueForum and a well known income newsletter. ValueForum costs a little over 200 per year. The income newsletter costs about 400 per year. I am up 11% on investments made because I heard about them on ValueForum (of course, I do my own research on everything but the ideas came from ValueForum and there was always some discussion of the pros and cons of each investment on VF). I am down 8% on investments made because I heard about them from the income newsletter. I might also add that I often hear about breaking events immediately on ValueForum and a day or two later the same information is finally available from the newsletter. Hmmm...... which service is the better value?" more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards